Trial
NCT05204147
Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers
Phase ISUSPENDEDOTHER/UNKNOWNConfidence: LOW
Sponsor
City of Hope Medical Center
Collaborators
National Cancer Institute (NCI)
Condition
Advanced Cancer
Intervention
Actinium Ac 225-DOTA-anti-CEA Monoclonal Antibody M5A
Why stopped
Drug Availability
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-22